Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumovax 23 in Healthy Adults in India
NCT00496093Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2005
- Primary completion
- Jan 2006
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Oct 2005; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00496093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496093.